Published July 23, 2026
Bayer's proposed $7.25 billion nationwide class settlement to resolve Roundup cancer claims moved toward a decisive moment this summer. A St. Louis City Circuit Court judge granted preliminary approval to the deal on March 4, 2026, and set a final "fairness hearing" for July 9, 2026, to decide whether the settlement should be approved for good. The agreement is designed to resolve most of the roughly 65,000 Roundup product liability claims still pending in state and federal courts nationwide, covering people who developed non-Hodgkin lymphoma after glyphosate exposure.
Getting to a fairness hearing didn't mean the fight was over. In the weeks before the deadline, more than 100 class members and roughly a dozen health care plans filed formal objections. On May 21, 2026, attorney Ashley Keller and the Tennessee firm Frazer PLC filed one of the more prominent objections in Missouri state court, arguing the deal is inadequate for people with non-Hodgkin lymphoma and calling out the roughly $675 million in attorney fees carved out of the settlement fund for the lawyers who negotiated it. Reported individual payouts under the settlement vary widely, from several thousand dollars up to $165,000 or more depending on exposure history and diagnosis, according to legal industry reporting.
Part of what makes this settlement unusual is that it doesn't just cover people already diagnosed — it creates a "futures" subclass covering anyone exposed to Roundup before February 17, 2026 who might develop non-Hodgkin lymphoma later, including children. Objectors argue that structure raises due-process concerns, since someone can't meaningfully evaluate compensation for an injury they don't yet have. Keller's firm went further, filing a notice attempting to move the matter into federal court, where it would land in front of Judge Vince Chhabria, the judge who has overseen most of the federal Roundup litigation for roughly a decade.
Judge Chhabria isn't part of approving this settlement — it moved through Missouri state court, not his federal docket — but he weighed in critically at an April 2026 hearing, describing the process by which the deal reached state court as "filthy." His comments are a reminder that this settlement doesn't tidily resolve the litigation: options and deadlines differ depending on whether a claim sits in the state class, was opted out, or remains in federal court. Anyone who was exposed to Roundup and developed cancer, or who hasn't yet had a claim evaluated, should get an individualized case review rather than assume the settlement automatically applies. See Atumio's Roundup case page for a free, no-obligation review, or start your case review directly.